本帖最后由 老马 于 2012-1-13 21:20 编辑 4 o! k4 b: s3 W# F q' @
7 D" f0 d% }; L, ~# y0 w爱必妥和阿瓦斯丁的比较
, A- _- v3 z1 l' x
: ^% g# m+ I. W$ [
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/7 b' i; o1 M( Q* e/ ]+ W S
$ t: m" J& [& x* F# o
; m& T, x8 f9 e9 l/ a5 x2 M* C7 _
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
* p& x8 d I. B0 m9 @==================================================
' u, X4 G2 @3 _% D0 i& ^Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)4 F9 B, D( V) M) i; y0 _ T
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.' B' W* l3 [0 }7 I0 B, I' n8 Z
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.! D3 i3 i( q, }& E) s/ \0 ?3 ~
|